Sequential immunohistochemistry: a promising new tool for the pathology laboratory. 2014

Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.

OBJECTIVE Current immunohistochemical methods to study the expression of multiple proteins in a single tissue section suffer from several limitations. In this article, we report on sequential immunohistochemistry (S-IHC), a novel, easy method that allows the study of numerous proteins in a single tissue section, while requiring very limited optimization. RESULTS In S-IHC, a tissue section is stained for multiple antibodies, with intermediate scanning of the section and elution of chromogen and antibodies. Overlays are made of the digital images, allowing assessment of multiple proteins in the same tissue section. We used S-IHC to study nine nodular lymphocyte-predominant Hodgkin lymphomas (NLPHLs) and 10 T-cell-rich and histiocyte-rich diffuse large B-cell lymphomas (T/HRBCLs) for expression of cyclin D1, CD20, and CD68. We observed cyclin D1 expression in single tumour cells in 44% of NLPHLs and 60% of T/HRBCLs. Comparison of S-IHC with classic single immunohistochemical staining revealed discrepancies in eight cases (42%), demonstrating the difficulty of differentiating tumour cells from histiocytes on morphological grounds, and stressing the additional value of S-IHC. CONCLUSIONS For research and diagnostic purposes, S-IHC is a promising technique that assesses the expression of numerous proteins in single tissue sections with complete architectural information, allowing phenotypic characterization of single cells.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D005260 Female Females
D006644 Histiocytes Macrophages found in the TISSUES, as opposed to those found in the blood (MONOCYTES) or serous cavities (SEROUS MEMBRANE). Histiocyte
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015214 Antigens, Differentiation, Myelomonocytic Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukemias and lymphomas. Differentiation Antigens, Myelomonocytic,Myelomonocytic Differentiation Antigens,Antigens, Myelomonocytic, Differentiation,Antigens, Myelomonocytic Differentiation
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D016393 Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. B-Cell Lymphoma,B Cell Lymphoma,B-Cell Lymphomas,Lymphoma, B Cell,Lymphomas, B-Cell

Related Publications

Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
September 1988, American journal of clinical pathology,
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
August 2016, Archives of pathology & laboratory medicine,
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
September 2007, Advances in anatomic pathology,
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
January 2005, Clinical nurse specialist CNS,
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
December 2007, The Malaysian journal of pathology,
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
August 2011, Journal of advanced nursing,
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
January 2022, PloS one,
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
June 2022, Gels (Basel, Switzerland),
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
January 2005, Indian journal of public health,
Michiel van den Brand, and Brigiet M Hoevenaars, and Jessica H M Sigmans, and Jos W R Meijer, and Patricia H J van Cleef, and Patricia J T A Groenen, and Konnie M Hebeda, and J Han J M van Krieken
August 2012, JPMA. The Journal of the Pakistan Medical Association,
Copied contents to your clipboard!